[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Synermore Biologics (Suzhou) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,31],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":21,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":28,"locationsCount":4},"100647451","an-expanded-access-program-for-syn023-in-rabies-treatment-100647451",false,"NCT07706907","An Expanded Access Program for SYN023 in Rabies Treatment","Sponsor-Initiated Expanded Access Program (SYN023-EAP-001) for SYN023 (Zamerovimab + Mazorelvimab): Compassionate Use of SYN023 in Patients With Confirmed or Suspected Life-Threatening Rabies Infection","Inclusion Criteria:\n\n* Must be ineligible for or lack access to other investigational or approved therapies\n* Must have no available alternative curative treatment options\n\nExclusion Criteria:\n\nNo standardized universal exclusion criteria are predefined for this Expanded Access Program.\n\n\\- Clinical contraindications identified on an individual basis by the treating critical care clinician","ALL","EXPANDED_ACCESS","This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.",[20],"Rabies",[20,22],"SYN023","AVAILABLE","2026-07-16",{"date":26,"type":27},"2026-07-17","ACTUAL",{"name":29,"class":30},"Synermore Biologics (Suzhou) Co., Ltd.","INDUSTRY",{"id":32,"slug":33,"hasResults":11,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":4,"eligibilityCriteria":37,"healthyVolunteers":11,"sex":16,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":43,"studyType":44,"phases":4,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100618106","real-world-evidence-study-of-syn023-in-children-exposed-to-rabies-100618106","NCT07327307","Real World Evidence Study of SYN023 in Children Exposed to Rabies","A Real-World Registry Study to Evaluate Clinical Protection Outcomes Following Post-Exposure Prophylaxis With Zamerovimab and Mazorelvimab Injection in Combination With Rabies Vaccine in Pediatric With Category III Rabies Exposure","Inclusion Criteria:\n\n1. Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity;\n2. Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is \\\u003C7 days;\n3. Have completed standardized wound management, injection of Zamerovimab and Mazorelvimab Injection \u002Fother passive immunization products, and the first dose of rabies vaccination within 24 hours prior to screening;\n4. The volunteer's guardian voluntarily agrees to their participation in the study and signs the informed consent form. Specifically: for volunteers under 8 years old, the guardian signs the informed consent form with the child's assent fully respected; for volunteers aged 8-17, the guardian signs the informed consent form, and the minor volunteer signs the minor assent form;\n5. Willing and able to comply with all study procedures, and is expected to be able to complete the full course of rabies vaccination and the 1-year follow-up as required (with no plans for long-term absence or relocation from the study area).\n\nExclusion Criteria:\n\n1. Based on inquiry, besides the current Category III rabies exposure, there is a history of bites by dogs, cats, mongooses, foxes, ferrets, skunks, bats, or raccoons within the past year;\n2. Other conditions considered by the investigator as unsuitable for participation in this study.","0 Years","17 Years",{"count":41,"type":42},232,"ESTIMATED","1 Year","OBSERVATIONAL","This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III rabies exposure who have received real-world Post-Exposure Prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection \u002F other passive immunization products combined with the rabies vaccine.\n\nParticipants will: (1) Have their clinical protection outcomes (rabies-free survival status) registered and evaluated on Day 90 and Day 365. (2) Have the option to provide a blood sample on Day 7 for Rabies Virus Neutralizing Antibody (RVNA) testing. (3) Have all adverse events (within 42 days) and all serious adverse events (within 126 days) after PEP administration collected and recorded.",[47],"Rabies Post-exposure Prophylaxis",[49,22,50],"rabies","pediatric","RECRUITING","2026-04-21",{"date":54,"type":27},"2026-04-23",{"date":56,"type":27},"2025-08-02",{"date":58,"type":42},"2026-12-31",{"name":29,"class":30},6,""]